A Randomized Controlled Pilot Study of a Culturally-Tailored Counseling Intervention to Increase Uptake of HIV Pre-exposure Prophylaxis Among Young Black Men Who Have Sex with Men in Washington, DC.
Adolescent
Adult
Black or African American
Anti-HIV Agents
/ therapeutic use
Counseling
/ methods
Culturally Competent Care
District of Columbia
Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination
/ therapeutic use
HIV Infections
/ prevention & control
Health Behavior
Homosexuality, Male
Humans
Male
Pilot Projects
Pre-Exposure Prophylaxis
/ statistics & numerical data
Sexual Behavior
Sexual and Gender Minorities
United States
Young Adult
Black men who have sex with men
Counseling
HIV
Preexposure prophylaxis
Journal
AIDS and behavior
ISSN: 1573-3254
Titre abrégé: AIDS Behav
Pays: United States
ID NLM: 9712133
Informations de publication
Date de publication:
Jan 2019
Jan 2019
Historique:
pubmed:
2
9
2018
medline:
19
3
2019
entrez:
2
9
2018
Statut:
ppublish
Résumé
Daily emtricitabine/tenofovor is effective at preventing HIV acquisition and is approved for HIV pre-exposure prophylaxis (PrEP). Blacks in the United States have a disproportionately high rate of HIV, and uptake of PrEP has been very low in this population. We conducted a pilot study in a high-prevalence city to test whether a culturally-tailored counseling center for young Black men who have sex with men (BMSM) positively impacted their access and uptake of PrEP. 50 young BMSM were randomized to either a PrEP counseling center group or a control group, and were then encouraged to obtain PrEP from a PrEP provider. At the end of 3 month study, six participants in the intervention group compared with none in the control group had initiated PrEP (p = 0.02). This pilot study demonstrates that a culturally-tailored counseling center might be an effective at increasing the uptake of PrEP in young BMSM.
Identifiants
pubmed: 30171452
doi: 10.1007/s10461-018-2264-5
pii: 10.1007/s10461-018-2264-5
pmc: PMC6344254
mid: NIHMS1505537
doi:
Substances chimiques
Anti-HIV Agents
0
Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination
0
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
105-115Subventions
Organisme : NIAID NIH HHS
ID : P30 AI117970
Pays : United States
Organisme : District of Columbia Developmental Center for AIDS Research
ID : 1P30AI117970-01
Références
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
N Engl J Med. 2010 Dec 30;363(27):2587-99
pubmed: 21091279
J Acquir Immune Defic Syndr. 2013 Apr 1;62(4):447-56
pubmed: 24135734
AIDS Behav. 2014 Jul;18(7):1272-8
pubmed: 24569888
AIDS Behav. 2014 Sep;18(9):1712-21
pubmed: 24965676
Am J Public Health. 2015 Feb;105(2):e75-82
pubmed: 25521875
N Engl J Med. 2015 Dec 3;373(23):2237-46
pubmed: 26624850
J Miss State Med Assoc. 2015 Dec;56(12):364-71
pubmed: 26975161
PLoS One. 2016 Jun 03;11(6):e0156592
pubmed: 27258374
J Infect Dis. 2016 Dec 15;214(12):1800-1807
pubmed: 27418048
AIDS Behav. 2017 May;21(5):1256-1267
pubmed: 27885552
Cogn Behav Pract. 2017 Feb;24(1):38-49
pubmed: 28392673
J Acquir Immune Defic Syndr. 2017 Jun 1;75(2):175-183
pubmed: 28498144
J Acquir Immune Defic Syndr. 2017 Jul 1;75 Suppl 3:S375-S382
pubmed: 28604442
Clin Trials. 2018 Feb;15(1):44-52
pubmed: 28862483